IP Library Granted Patent US 8,609,107
Granted Patent B2
US 8,609,107 · App. 13/613,827 · Granted Dec 17, 2013

Nucleic acid and amino acid sequences relating to

Inventors: Lynn Doucette-Stamm (Framingham, MA); David Bush (Somerville, MA); Qiandong Zeng (Waltham, MA); Timothy Opperman (Somerville, MA); Chad Eric Houseweart (Waltham, MA)
Assignee: Sanofi Pasteur Limited
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,609,107
App. No.
13/613,827
Granted
Dec 17, 2013
Kind
B2
Abstract

The invention provides methods of treating subject with polypeptides having at least 80% identity to SEQ ID NO: 5326. The methods stimulate an immune response in the subject and provide methods for prevention and treatment of pathological conditions resulting from bacterial infection.

Claims (11)

1. A method of treating a subject, comprising the step of administering a composition that includes a polypeptide having at least 80% identity to the amino acid sequence of SEQ ID NO: 5326.

2. The method of claim 1 , wherein the polypeptide elicits an immune response when administered to the subject.

3. The method of claim 2 , wherein the immune response is an immune response against S. pneumonia.

4. The method of claim 1 , wherein the polypeptide provides a immune response against S. pneumonia infection that results in disease when administered to the subject.

5. The method of claim 1 , wherein the composition includes a pharmaceutically acceptable carrier.

6. The method of claim 5 , wherein the composition further includes an adjuvant.

7. The method of claim 6 , wherein the adjuvant is at least one member selected from the group consisting of aluminum hydroxide, N-acetyl-muramyl-L-threonyl-D-isoglutamine, N-acetyl-nor-muramyl-L-alanyl-D-isoglutamine, N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-(1′-2′-dipalmitoyl-sn-glycero-3-hydroxyphos-phoryloxy)-ethylamine; cholera toxin, a non-toxic derivative of cholera toxin, procholeragenoid, fungal polysaccharides, muramyl dipeptide, muramyl dipeptide derivatives, phorbol esters, labile toxin of E. coli , non- S. pneumoniae bacterial lysates, block polymers and saponins.

8. The method of claim 1 , wherein the isolated polypeptide has at least 90% identity to SEQ ID NO: 5326.

9. The method of claim 1 , wherein the isolated polypeptide has at least 95% identity to SEQ ID NO: 5326.

10. The method of claim 1 , wherein the isolated polypeptide has at least 98% identity to SEQ ID NO: 5326.

11. The method of claim 1 , wherein the isolated polypeptide has at least 99% identity to SEQ ID NO: 5326.

Assignments (3)
CHANGE OF NAME Recorded May 1, 2013
From: AVENTIS PASTEUR LIMITED/AVENTIS PASTEUR LIMITEE
To: SANOFI PASTEUR LIMITED/SANOFI PASTEUR LIMITEE
Reel/Frame 030325/0136 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 25, 2013
From: GENOME THERAPEUTICS CORPORATION
To: AVENTIS PASTEUR LTD
Reel/Frame 030286/0479 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 11, 2013
From: DOUCETTE-STAMM, LYNN; BUSH, DAVID; ZENG, QIANDONG; OPPERMAN, TIMOTHY; HOUSEWEART, CHAD ERIC
To: GENOME THERAPEUTICS CORPORATION
Reel/Frame 030198/0930 →
Continuity (8)
Division 11796731 · Apr 27, 2007
Division 11028458 · Dec 30, 2004
Continuation 10640833 · Aug 14, 2003
Continuation 09583110 · May 26, 2000
Continuation In Part 09107433 · Jun 30, 1998
Provisional Application 60085131 · May 12, 1998
Provisional Application 60051553 · Jul 2, 1997
Related Publication 20130078271A1 · Mar 28, 2013